Emerging technologies in autoantibody testing for rheumatic diseases

Simple item page
dc.contributor.authorOlsen, Nancy J
dc.contributor.authorChoi, May Y
dc.contributor.authorFritzler, Marvin J
dc.date.accessioned2018-11-07T17:04:37Z
dc.date.available2018-11-07T17:04:37Z
dc.date.issued2017-07-24
dc.date.updated2018-11-07T17:04:37Z
dc.description.abstractAbstract Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.
dc.identifier.citationArthritis Research & Therapy. 2017 Jul 24;19(1):172
dc.identifier.doihttps://doi.org/10.1186/s13075-017-1380-3
dc.identifier.urihttp://hdl.handle.net/1880/109031
dc.identifier.urihttps://doi.org/10.11575/PRISM/45916
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.titleEmerging technologies in autoantibody testing for rheumatic diseases
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13075_2017_Article_1380.pdf
Size:
1.02 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications